Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
Clinical data supporting the expanded approval come from the Phase I/II open-label multi-centre BUR-CL207 trial.
Drug Development
Cellares and Papillon partner for PPL-001 manufacturing automation
EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168
Halozyme and Incyte sign licence agreement for INCA033989 formulations
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Aptar unveils framework for injectable drug delivery systems
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
JCVI issues recommendation on adolescent MenB vaccination in UK
